Search research articles
Contact Us
Filters
Showing results (31-40 of 50) with videos related to
Page
of 5
Sort By:
BJU International
|
July 12, 2001
Selective urological evaluation in men with febrile urinary tract infection
P Ulleryd, B Zackrisson, G Aus, et al.
BJU International
|
September 1, 1999
Prostatic involvement in men with febrile urinary tract infection as measured by serum prostate-specific antigen and transrectal ultrasonography
P Ulleryd, B Zackrisson, G Aus, et al.
Urology
|
April 1, 1996
Reference range of prostate-specific antigen after transurethral resection of the prostate
G Aus, S Bergdahl, R Frösing, et al.
European Urology
|
July 21, 2001
Outcome of laterally directed sextant biopsies of the prostate in screened males aged 50--66 years. Implications for sampling order
G Aus, S Bergdahl, J Hugosson, et al.
Urology
|
August 12, 1999
Tumor cell proliferation in prostate cancer after 3 months of neoadjuvant LHRH analogue treatment is a prognostic marker of recurrence after radical prostatectomy
G Ahlgren, K Pedersen, S Lundberg, et al.
The Prostate
|
February 19, 2000
Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment
G Ahlgren, K Pedersen, S Lundberg, et al.
Scandinavian Journal of Urology and Nephrology
|
February 12, 1998
Diagnosis of prostate cancer: optimal number of prostate biopsies related to serum prostate-specific antigen and findings on digital rectal examination
G Aus, G Ahlgren, J Hugosson, et al.
European Urology
|
January 1, 1994
Effects of 3 months' neoadjuvant hormonal treatment with a GnRH analogue (triptorelin) prior to radical retropubic prostatectomy on prostate-specific antigen and tumour volume in prostate cancer
G Aus, S Brändstedt, M Häggman, et al.
The Journal of Urology
|
February 25, 1998
Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen
P Lodding, G Aus, S Bergdahl, et al.
BJU International
|
June 10, 2000
Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden
J Hugosson, G Aus, C Becker, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 50) with videos related to
Sort By:
Page
of 5
BJU International
|
July 12, 2001
Selective urological evaluation in men with febrile urinary tract infection
P Ulleryd, B Zackrisson, G Aus, et al.
BJU International
|
September 1, 1999
Prostatic involvement in men with febrile urinary tract infection as measured by serum prostate-specific antigen and transrectal ultrasonography
P Ulleryd, B Zackrisson, G Aus, et al.
Urology
|
April 1, 1996
Reference range of prostate-specific antigen after transurethral resection of the prostate
G Aus, S Bergdahl, R Frösing, et al.
European Urology
|
July 21, 2001
Outcome of laterally directed sextant biopsies of the prostate in screened males aged 50--66 years. Implications for sampling order
G Aus, S Bergdahl, J Hugosson, et al.
Urology
|
August 12, 1999
Tumor cell proliferation in prostate cancer after 3 months of neoadjuvant LHRH analogue treatment is a prognostic marker of recurrence after radical prostatectomy
G Ahlgren, K Pedersen, S Lundberg, et al.
The Prostate
|
February 19, 2000
Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment
G Ahlgren, K Pedersen, S Lundberg, et al.
Scandinavian Journal of Urology and Nephrology
|
February 12, 1998
Diagnosis of prostate cancer: optimal number of prostate biopsies related to serum prostate-specific antigen and findings on digital rectal examination
G Aus, G Ahlgren, J Hugosson, et al.
European Urology
|
January 1, 1994
Effects of 3 months' neoadjuvant hormonal treatment with a GnRH analogue (triptorelin) prior to radical retropubic prostatectomy on prostate-specific antigen and tumour volume in prostate cancer
G Aus, S Brändstedt, M Häggman, et al.
The Journal of Urology
|
February 25, 1998
Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen
P Lodding, G Aus, S Bergdahl, et al.
BJU International
|
June 10, 2000
Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden
J Hugosson, G Aus, C Becker, et al.
Page
of 5